Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph Disease (MJD), is the most common dominant ataxia worldwide. The disease is caused by a CAG trinucleotide repeat expansion in the ATXN3 gene, which encodes the protein ataxin-3. This autosomal dominant disorder leads to progressive neurodegeneration primarily affecting the cerebellum, brainstem, and spinal cord, resulting in ataxia, dysarthria, ophthalmoplegia, and pyramidal signs.
| SCA3 / MJD |
|---|
| Gene Symbol | ATXN3 |
| Full Name | Ataxin-3 |
| Chromosomal Location | 14q32.1 |
| NCBI Gene ID | [6312](https://www.ncbi.nlm.nih.gov/gene/6312) |
| OMIM | [607047](https://www.omim.org/entry/607047) |
| UniProt ID | [Q9UHD8](https://www.uniprot.org/uniprotkb/Q9UHD8/entry) |
| Inheritance | Autosomal Dominant |
| Repeat Type | CAG (Polyglutamine) |
| Normal Repeat | 12-44 |
| Pathogenic Repeat | 51-86 |
Ataxin-3 is a 361-amino acid protein encoded by the ATXN3 gene located on chromosome 14q32.1. The protein contains:
- N-terminal Josephin domain (JD): A catalytic domain with deubiquitinating enzyme (DUB) activity
- C-terminal polyglutamine (polyQ) tract: The pathogenic expansion occurs in this region
- Multiple VCP/p97 binding motifs (VBM): Involved in protein quality control
- Nuclear localization signals (NLS): Regulates subcellular trafficking
The Josephin domain functions as a deubiquitinating enzyme (DUB) that hydrolyzes ubiquitin chains, particularly those linked through Lys63 and Lys48. This activity is crucial for:
- Protein quality control: Removing ubiquitin from misfolded proteins for degradation
- Transcriptional regulation: Modulating histone ubiquitination
- Stress response: Processing ubiquitin conjugates during cellular stress
In its normal state, ataxin-3 participates in several cellular processes:
- Protein homeostasis: As a DUB, it regulates the ubiquitin-proteasome system (UPS)
- DNA repair: Associates with transcriptional regulators and DNA damage response proteins
- Mitochondrial function: Interacts with mitochondrial quality control machinery
- Autophagy regulation: Modulates both selective autophagy and mitophagy
Ataxin-3 is ubiquitously expressed with high levels in:
- Cerebellar Purkinje cells
- Brainstem neurons
- Spinal cord motor neurons
- Peripheral nervous system
- Heart, liver, and skeletal muscle
The CAG repeat expansion in ATXN3 results in an abnormally long polyglutamine (polyQ) tract in the ataxin-3 protein. The number of CAG repeats correlates with:
- Age of onset: More repeats → earlier onset
- Disease severity: Longer repeats → more severe phenotype
- Anticipation: Paternal transmission often leads to earlier onset in offspring
The expanded polyQ tract triggers pathogenesis through multiple mechanisms:
¶ Protein Misfolding and Aggregation
The expanded polyQ sequence causes conformation changes in ataxin-3, leading to:
- Misfolding into beta-sheet rich structures
- Oligomerization into toxic species
- Formation of large aggregtes
- Sequestration of essential cellular proteins
Importantly, ataxin-3 aggregates colocalize with other proteins in neuronal inclusions, including ubiquitin, p62, and TDP-43.
ATXN3 expansions disrupt normal transcriptional programs by:
- Sequestering transcription factors in aggregates
- Altering histone acetylation/deacetylation balance
- Dysregulating brain-derived neurotrophic factor (BDNF) expression
- Affecting mitochondrial biogenesis genes
SCA3 neurons exhibit profound mitochondrial abnormalities:
- Reduced complex I and IV activity
- Decreased ATP production
- Increased reactive oxygen species (ROS)
- Impaired calcium buffering
- Damaged mitochondrial dynamics (fission/fusion)
The autophagy-lysosome pathway is compromised in SCA3:
- Reduced autophagic flux
- Impaired mitophagy
- Accumulation of damaged organelles
- Failure to clear mutant protein aggregates
Neuronal calcium homeostasis is disrupted:
- Enhanced calcium release from ER stores
- Mitochondrial calcium overload
- Dysregulated calcium-dependent proteases
- Altered synaptic plasticity
A chronic inflammatory response develops:
- Activated microglia in affected brain regions
- Elevated pro-inflammatory cytokines
- Complement system activation
- Blood-brain barrier disruption
The characteristic neuropathological features of SCA3 include:
- Neuronal loss: Degeneration of Purkinje cells, brainstem nuclei, and spinal cord neurons
- Neuronal intranuclear inclusions (NII): Aggregates of mutant ataxin-3 in neuronal nuclei
- Gliosis: Prominent astrocytosis and microgliosis
- Spiny dendrite degeneration: Unique dendritic pathology in Purkinje cells
| Symptom |
Description |
Frequency |
| Ataxia |
Progressive cerebellar gait and limb ataxia |
Universal |
| Dysarthria |
Scanning, explosive speech |
>90% |
| Ophthalmoplegia |
Horizontal gaze palsy, nystagmus |
>80% |
| Pyramidal signs |
Hyperreflexia, spasticity |
60-80% |
| Bulbar signs |
Dysphagia, dysphonia |
50-70% |
| Peripheral neuropathy |
Distal weakness, sensory loss |
40-60% |
Three clinical phenotypes are recognized:
- Type I (Azorean disease): Early onset, rapid progression, prominent pyramidal/extrapyramidal signs
- Type II: Intermediate onset, ataxia with spasticity
- Type III: Late onset, primarily ataxic symptoms
- Duration: 15-25 years from onset to death
- Wheelchair: Typically required 10-15 years after onset
- Cause of death: Respiratory complications, aspiration pneumonia
- Autosomal dominant: One mutant allele is sufficient
- Anticipation: Earlier onset in successive generations (especially paternal)
- Penetrance: Near complete by age 70
Several genetic factors modify disease severity:
- CAG repeat length: Primary determinant of age of onset
- Hsp70 polymorphisms: Affect protein aggregation
- Autophagy gene variants: Modify clearance of mutant protein
- Mitochondrial haplogroups: Influence energy metabolism
- Transgenic mice: Express human ATXN3 with expanded CAG repeats
- Knock-in mice: Murine ATXN3 with expanded repeats
- Conditional models: Inducible expression systems
- Aggregate formation precedes behavioral deficits
- Mitochondrial dysfunction occurs early
- Autophagy modulation alters disease progression
- Gene silencing extends survival
RNA interference (RNAi) and antisense oligonucleotides (ASOs) targeting ATXN3 have shown promise in preclinical models:
- AAV-delivered shRNA reduces mutant protein
- ASOs decrease ATXN3 expression
- Allele-specific silencing for heterozygous targeting
| Approach |
Target |
Status |
| DUB modulators |
Ataxin-3 activity |
Preclinical |
| Autophagy inducers |
Protein clearance |
Preclinical |
| Mitochondrial protectants |
Bioenergetics |
Preclinical |
| Antioxidants |
ROS |
Clinical trials |
| Calcium stabilizers |
Ca2+ dysregulation |
Preclinical |
- AAV-mediated delivery of therapeutic genes
- CRISPR-based approaches for repeat contraction
- Gene replacement strategies
- Physical therapy for ataxia
- Speech therapy for dysarthria
- Botulinum toxin for spasticity
- Assistive devices for mobility
- Neurofilament light chain (NfL): Elevated in serum/CSF
- Tau protein: Altered phosphorylation patterns
- YKL-40: Marker of neuroinflammation
- MRI: Cerebellar and brainstem atrophy
- PET: Hypometabolism in affected regions
- Diffusion tensor imaging: White matter damage
Key insights from model systems:
- Aggregate spread: Misfolded ataxin-3 can propagate between cells
- Oligotoxicity: Soluble oligomers may be more toxic than large aggregates
- Network dysfunction: Early synaptic deficits precede neuron loss
- Protective mechanisms: Autophagy upregulation is beneficial
- ATXN1 — Spinocerebellar ataxia type 1
- ATXN2 — Spinocerebellar ataxia type 2 / ALS
- ATXN7 — Spinocerebellar ataxia type 7
- Antisense oligonucleotide trials
- Gene therapy trials
- Biomarker natural history studies
- CRISPR-based gene editing
- Protein aggregation inhibitors
- Neuroregeneration approaches
- Biomarker-driven clinical trials
- Kawaguchi et al., Expansion of CAG repeats in ataxin-3. Nature. 1994
- Lima et al., Ataxin-3 function in neurodegeneration. Brain. 2005
- Nagai et al., Mitochondrial dysfunction in SCA3. J Neurol Sci. 2013
- Correia et al., Molecular mechanisms in SCA3/MJD. Front Mol Neurosci. 2015
- Martins et al., Autophagy dysfunction in SCA3. Autophagy. 2016
- Gatchel et al., Recent advances in SCA3. Cerebellum. 2017
- McInroy et al., ATXN3 deubiquitinase function and disease. J Mol Biol. 2021
- Sato et al., Biomarkers for SCA3. Neurology. 2023
- Kawaguchi et al., Expansion of CAG repeats in ataxin-3 underlies SCA3 (1994)
- Lima et al., Ataxin-3 function in neurodegeneration (2005)
- Nagai et al., Mitochondrial dysfunction in SCA3 (2013)
- Correia et al., Molecular mechanisms in SCA3/MJD (2015)
- Martins et al., Autophagy dysfunction in SCA3 (2016)
- Rinaldi et al., Proteostasis impairment in polyglutamine diseases (2015)
- Gatchel et al., Recent advances in SCA3 (2017)
- Garden et al., Spiny dendrite pathology in SCA3 (2012)
- McInroy et al., ATXN3 deubiquitinase function and disease (2021)
- Chaves et al., Mitochondrial respiratory chain in SCA3 (2011)
- Mas更适合 et al., Therapeutic approaches for SCA3 (2022)
- Koch et al., Tangled proteins in SCA3 (2011)
- Blount et al., Inflammatory response in SCA3 (2019)
- Bettencourt et al., Genetic modifiers in SCA3 (2016)
- Rodriguez et al., Transcriptional dysregulation in SCA3 (2018)
- Carvalho et al., Calcium dysregulation in SCA3 (2018)
- Figueiredo et al., Neuroinflammation in SCA3 (2019)
- 工作组 et al., Gene therapy for SCA3 (2023)
- Sato et al., Biomarkers for SCA3 (2023)
- Chiacchiarini et al., AAV gene therapy in SCA3 mouse models (2022)
- Moro et al., 14-3-3 proteins in SCA3 pathogenesis (2019)